Smoking Cessation Pregnancy Data Required For Alternative Warning Use
This article was originally published in The Tan Sheet
Executive Summary
OTC nicotine-replacement therapy manufacturers who wish to use a pregnancy/breastfeeding warning different from new, FDA-revised labeling "will have to provide data to support alternative wording," the agency says.
You may also be interested in...
Make Smoking Cessation OTCs As Available As Cigarettes – Petition
A citizen petition asking FDA to allow OTC nicotine replacement therapy products to be sold wherever cigarettes are sold and at similar prices has been filed by the New York State Department of Health
Nicotine Replacement Therapy Prop 65 Warning Unfounded, FDA Tells Court
A California appellate court's ruling that a Prop 65 warning for nicotine replacement therapies is not federally preempted would require product manufacturers to use warning language FDA has determined lacks scientific support, the agency says
Habitrol labeling changes
FDA approves supplemental NDA 20-076/S-021 for labeling changes to Novartis' Habitrol smoking cessation patch on July 15. New packaging will incorporate current pregnancy/breastfeeding warning, as requested by FDA in 2001 (1"The Tan Sheet" August 27, 2001, p. 3). Changes will appear on "Drug Facts" box of 7 mg, 14 mg and 21 mg Habitrol cartons. Revised labeling also will be reflected on multi-dose Habitrol kit, which was approved as the first 3-in-1 smoking cessation offering in July (2"The Tan Sheet" July 22, 2002, p. 4)...